Kelly Boothe
Investor Relations Kontakt bei Carmot Therapeutics, Inc.
Aktive Positionen von Kelly Boothe
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Investor Relations Kontakt | - | - |
| Public Communications Contact | - | - |
Karriereverlauf von Kelly Boothe
Ehemalige bekannte Positionen von Kelly Boothe
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SPYRE THERAPEUTICS, INC. | Investor Relations Kontakt | - | - |
| Public Communications Contact | - | - |
Statistik
International
| Vereinigte Staaten | 3 |
Operativ
| Investor Relations Contact | 2 |
| Public Communications Contact | 2 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
- Börse
- Insiders
- Kelly Boothe
- Erfahrung
